Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BIO CEO & Investor Conference In Brief

Executive Summary

CytRx looks to put arimoclomal on track: CytRx plans to submit a toxicology report to FDA in the second quarter to facilitate the return of its Phase II candidate arimoclomal for Amyotrophic Lateral Sclerosis to the clinic, VP-Business Development David Haen said during the BIO CEO & Investor Conference in New York Feb. 9-10. The drug was put on clinical hold by FDA in January 2008 due to toxicology concerns stemming from an earlier rat study. CytRx conducted another study to address FDA's concerns. Arimoclomal is one of the firm's key internal assets; the firm is seeking to partner the drug. "We have had this cloud, this clinical hold, but we do expect it to be resolved," Haen said

You may also be interested in...

Pfizer Sees No Future In NicOx Glaucoma Candidate After Failure In Japanese Phase II Trial

Collaboration turns to diabetic retinopathy after Pfizer backs away from PF-03187207 development.

Pfizer Neuroscience Cuts Back To Alzheimer’s, Psychosis

Firm partners in areas it dropped internally and in some new ones.

GSK Sees Much More In Sirtris Than Meets The Eye – IN VIVO Blog

How does an early-stage biotech company, focused on a single set of targets, with a lone compound in early Phase II and everything else preclinical (including its most promising compounds), command a buyout price of $720 million?

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts